Shoji Mikio
Department of Neurology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8216, Japan.
Int J Alzheimers Dis. 2011;2011:564321. doi: 10.4061/2011/564321. Epub 2011 May 30.
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, and phosphorylated tau are the most sensitive biomarkers for diagnosis of Alzheimer's disease (AD) and prediction of onset of AD from mild cognitive impairment (MCI). Based on this progress, new diagnostic criteria for AD, MCI, and preclinical AD were proposed by National Institute of Aging (NIA) and Alzheimer's Association in August 2010. In these new criteria, progress in biomarker identification and amyloid imaging studies in the past 10 years have added critical information. Huge contributions of basic and clinical studies have established clinical evidence supporting these markers. Based on this progress, essential therapy for cure of AD is urgently expected.
本文总结了痴呆生物标志物研究的最新进展。脑脊液Aβ40、Aβ42、总tau蛋白和磷酸化tau蛋白是诊断阿尔茨海默病（AD）以及预测从轻度认知障碍（MCI）发展为AD的最敏感生物标志物。基于这一进展，美国国立衰老研究所（NIA）和阿尔茨海默病协会于2010年8月提出了AD、MCI和临床前AD的新诊断标准。在这些新标准中，过去10年生物标志物鉴定和淀粉样蛋白成像研究的进展增添了关键信息。基础研究和临床研究的巨大贡献确立了支持这些标志物的临床证据。基于这一进展，人们迫切期待能找到治愈AD的根本疗法。
